Long-term suppression of hyperparathyroidism by phosphate binders in uremic children
- 30 Downloads
Forty-five children with stable chronic renal failure, not on dialysis, were treated conservatively with a regimen of mild dietary phosphate restriction and high-dose phosphate binders for up to 5 years. Both aluminum hydroxide and calcium carbonate were used initially, but almost all patients were taking calcium carbonate towards the end of the period. Serum immunoreactive parathyroid hormone concentrations were significantly decreased and were within the normal range after 1 year and remained normal during treatment. There was no significant change in renal function over the same treatment period. We conclude that calcium carbonate should be used as the phosphate binder of choice in the long-term suppression of hyperphosphatemia and hyperparathyroidism in uremic children.
Key wordsChronic renal failure Hyperparathyroidism Phosphate binder Aluminum hydroxide Calcium carbonate
Unable to display preview. Download preview PDF.
- 6.Sedman AB, Miller NL, Warady BA, Lunn GM, Alfrey AC (1984) Aluminum loading in children with chronic renal failure. Kidney Int 26: 201–204Google Scholar
- 8.Moriniere PH, Roussel A, Tahiri Y, de Fremont JF, Mautel G, Jandon MC, Gueris J, Fournier A (1982) Substitution of aluminum hydroxide by high doses of calcium carbonate in patients on chronic hemodialysis: disappearance of hyperaluminaemia and equal control of hyperparathyroidism. Proc Eur Dial Transplant Assoc 19: 784–787Google Scholar
- 9.Mak RHK, Turner C, Thompson T, Powell H, Haycock GB, Chantler C (1985) Suppression of secondary hyperparathyroidism in children with chronic renal failure by high dose phosphate binders: calcium carbonate versus aluminum hydroxide. Br Med J 291: 623–627Google Scholar
- 14.Llach F, Massry SG, Koffler A, Malluche HH, Singer FR, Brickman AS, Kurokawa K (1977) Secondary hyperparathyroidism in early renal failure: role of phosphate retention (abstract). Clin Res 25: 507AGoogle Scholar
- 15.Biswas CK, Arze RS, Ramos JM, Ward MK, Dewar JH, Kerr DN, Kenward DH (1982) Effect of aluminum hydroxide on serum ionised calcium, immunoreactive parathyroid hormone and aluminum in chronic renal failure. Br Med J 284: 776–778Google Scholar
- 16.Brown EM, Wilson RE, Eastman RC, Pallotta J, Marynick S (1982) Abnormal regulation of parathyroid hormone release by calcium in secondary hyperparathyroidism due to chronic renal failure. J Clin Endocrinol Metab 84: 172–179Google Scholar
- 18.Ward MK, Ellis HA, Feest TG, Parkinson IS, Kerr DN (1978) Osteomalacic dialysis osteodystrophy: evidence for a water-borne aetiological agent, probably aluminum. Lancet I: 841–845Google Scholar
- 21.Tougaard LE, Sorenson E, Brochner-Mortensen J, Christensen MS, Rodbro P, Sorensen AWS (1976) Controlled trial of 1-alpha-hydroxycholecalciferol in chronic renal failure. Lancet I: 1044–1048Google Scholar
- 22.Christiansen C, Rodbro P, Christensen MS, Hartnack B, Transbol I (1978) Deterioration of renal function during treatment of chronic renal failure with 1,25 dihydroxycholecalciferol. Lancet II: 700–703Google Scholar